Bao Yunfei, Feng Zhihao, Niu Yanyan, Hu Qing, Liu Haijie, Zhang Hongbo, Li Jianling
Department of Anesthesiology, Affiliated Hospital of Chengde Medical College; Hebei Key Laboratory of Panvascular Diseases, Chengde, Hebei, 067000, China.
Chengde Medical College, Chengde, Hebei, 067000, China.
BMC Anesthesiol. 2025 Jul 21;25(1):356. doi: 10.1186/s12871-025-03220-w.
Acute lung injury (ALI) is a common complication of endotoxemia, which carries a high risk of morbidity and mortality. Currently, no effective drugs exist to treat endotoxin-induced ALI. This study evaluated esketamine's protective effects against endotoxin-induced ALI and explored its underlying mechanisms.
Cecal ligation and puncture (CLP) was used to create a rat model of endotoxin-induced ALI. Esketamine (10 mg/kg) was injected into the tail vein of rats for drug treatment. The murine sepsis score (MSS) was used to evaluate the state of rats. Hematoxylin and eosin (HE) staining was used to evaluate lung tissue morphology and calculate the lung injury scores. The degree of lung tissue edema was assessed using the wet-to-dry weight (W/D) ratio. The expressions of caspase-11 and gasdermin D (GSDMD)-N, linked to the atypital pyroptosis pathway, were examined using immunohistochemistry (IHC) and western blot (WB) analysis. Caspase-11 and GSDMD mRNA levels were determined using quantitative real-time polymerase chain reaction (qRT-PCR). The expression of PI3K/AKT pathway was assessd using western blotting analysis. Interleukin (IL)-1β levels were quantified via enzyme-linked immunosorbent assay (ELISA).
Esketamine treatment improved lung tissue structure, reduced pulmonary edema, and mitigated the inflammatory response in ALI. Esketamine inhibited caspase-11 and GSDMD expressions and decreased IL-1β levels, while reversing the inhibition of the PI3K/AKT pathway in ALI.
Esketamine mitigates CLP-induced ALI by suppressing the caspase-11-GSDMD pathway and reducing inflammation. The PI3K/AKT pathway may be involved in these protective effects.
急性肺损伤(ALI)是内毒素血症的常见并发症,具有较高的发病和死亡风险。目前,尚无有效药物可治疗内毒素诱导的ALI。本研究评估了艾司氯胺酮对内毒素诱导的ALI的保护作用,并探讨其潜在机制。
采用盲肠结扎穿孔术(CLP)建立内毒素诱导的ALI大鼠模型。将艾司氯胺酮(10mg/kg)注入大鼠尾静脉进行药物治疗。使用小鼠脓毒症评分(MSS)评估大鼠状态。采用苏木精-伊红(HE)染色评估肺组织形态并计算肺损伤评分。使用湿重与干重(W/D)比值评估肺组织水肿程度。采用免疫组织化学(IHC)和蛋白质印迹(WB)分析检测与非典型细胞焦亡途径相关的半胱天冬酶-11和gasdermin D(GSDMD)-N的表达。使用定量实时聚合酶链反应(qRT-PCR)测定半胱天冬酶-11和GSDMD mRNA水平。采用蛋白质印迹分析评估PI3K/AKT通路的表达。通过酶联免疫吸附测定(ELISA)定量白细胞介素(IL)-1β水平。
艾司氯胺酮治疗改善了肺组织结构,减轻了肺水肿,并减轻了ALI中的炎症反应。艾司氯胺酮抑制半胱天冬酶-11和GSDMD表达,降低IL-1β水平,同时逆转ALI中PI3K/AKT通路的抑制。
艾司氯胺酮通过抑制半胱天冬酶-11-GSDMD通路并减轻炎症来减轻CLP诱导的ALI。PI3K/AKT通路可能参与这些保护作用。